Cellosaurus logo
expasy logo

Cellosaurus KK (CVCL_F844)

[Text version]
Cell line name KK
Accession CVCL_F844
Resource Identification Initiative To cite this cell line use: KK (RRID:CVCL_F844)
Comments Part of: MD Anderson Cell Lines Project.
Population: Japanese.
Doubling time: ~4 days (Note=At 70th passage) (PubMed=8148309); 31 hours (PubMed=8375936).
Omics: Genome sequenced.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Transcriptome analysis by microarray.
Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
Disease Ovarian clear cell adenocarcinoma (NCIt: C40078)
Clear cell adenocarcinoma of the ovary (ORDO: Orphanet_398971)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 46Y
Category Cancer cell line
STR profile Source(s): PubMed=30485824

Markers:
AmelogeninX
CSF1PO11,12
D5S81810,11
D7S82010,11
D13S3178,11
D16S53911,12
D21S1130,31.2
TH017,9
TPOX8,9
vWA14,17

Run an STR similarity search on this cell line
Web pages https://tcpaportal.org/mclp/
Publications

PubMed=8148309
Sasa H., Ishii K., Hirata J., Kikuchi Y., Nagata I., Kawai T., Senoo A., Sugita M., Sugishita T., Tenjin Y.
Establishment and characterization of a CA125-producing human ovarian clear cell carcinoma cell line.
Hum. Cell 6:279-286(1993)

PubMed=8375936; DOI=10.1002/ijc.2910550332
Hirata J., Kikuchi Y., Kita T., Imaizumi E., Tode T., Ishii K., Kudoh K., Nagata I.
Modulation of sensitivity of human ovarian cancer cells to cis-diamminedichloroplatinum(II) by 12-O-tetradecanoylphorbol-13-acetate and D,L-buthionine-S,R-sulphoximine.
Int. J. Cancer 55:521-527(1993)

PubMed=7844449
Ishii K., Kita T., Kudo K., Hisano A., Hirata J., Imaizumi E., Tode T., Kikuchi Y., Nagata I.
Circumvention of cisplatin resistant ovarian cancer cells by antiestrogens.
Nihon Sanka Fujinka Gakkai Zasshi 47:19-26(1995)

PubMed=15677628; DOI=10.1093/carcin/bgi032
Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Carcinogenesis 26:923-930(2005)

PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567
Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K., Hirohashi S., Inazawa J., Imoto I.
Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Cancer Res. 67:7095-7105(2007)

PubMed=20081105; DOI=10.1210/me.2009-0295
Nagaraja A.K., Creighton C.J., Yu Z.-F., Zhu H.-F., Gunaratne P.H., Reid J.G., Olokpa E., Itamochi H., Ueno N.T., Hawkins S.M., Anderson M.L., Matzuk M.M.
A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.
Mol. Endocrinol. 24:447-463(2010)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096
Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M., Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R., Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J., Velculescu V.E., Scharpf R.B.
Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.
Cell Rep. 25:2617-2633(2018)

Cross-references
Cell line databases/resources CGH-DB; 328-2
Encyclopedic resources Wikidata; Q54899964
Gene expression databases GEO; GSM416676
GEO; GSM659379
Polymorphism and mutation databases Cosmic; 931361
Cosmic; 1223313
Cosmic; 1328072
Cosmic; 1434897
Cosmic; 2074242
Cosmic; 2482702
Entry history
Entry creation11-Feb-2013
Last entry update29-Jun-2023
Version number16